“hDOS”: An automated hybrid diffuse optical device for real-time non-invasive tissue monitoring—precision and in vivo validation
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Significance
A new platform/device is presented that advances hybrid diffuse optical monitors closed to clinical practice, bridging the gap between research-grade optical systems and practical bedside applications. Traditional devices often lack automation, multi-parameter functionality, and operator independence, hence, limiting their usability in demanding clinical environments. By offering automation, user-friendly operation, and overcoming the typical limitations of continuous-wave near-infrared spectroscopy, the hybrid diffuse optical platform (hDOS) provides a more accurate and reliable assessment of both oxygenation and perfusion. This innovation is particularly valuable for monitoring critically ill patients, where precise real-time measurements can directly influence patient management and outcomes.
Aim
To design, validate, and characterize the platform hDOS that integrates time-domain near-infrared spectroscopy, diffuse correlation spectroscopy, and a pulse oximeter with an automated vascular occlusion test (VOT). The platform aims to support continuous monitoring and the assessment of peripheral microvascular, and metabolic functions in both clinical and field settings.
Approach
The validation strategy for the hDOS device follows a comprehensive approach that goes beyond conventional optical performance assessments. Rather than solely verifying fundamental system parameters, the evaluation comprises of real-world usability, operator and patient safety, and clinical implementation. The device’s precision and usability were rigorously tested in vivo through test-retest measurements and comparisons with a commercially available device (INVOS 5100C). This was subsequently followed by a seven-month clinical evaluation at Parc Taulí Hospital Universitari.
Results
The device underwent extensive validation, accumulating over 200 hours of usage across approximately 150 measurement sessions. The hDOS device exhibited two-fold lower inter-subject and intra-subject variability in baseline tissue oxygen saturation compared to the INVOS 5100C. Furthermore, during a a vascular occlusion challenge, statistically significant differences were observed between the two systems across all extracted parameters. Finally, as a proof of concept, hDOS successfully detected differences in the microvasculature between a general mixed ICU patient cohort ( n = 100) and a healthy control group ( n = 37).
Conclusions
Overall, hDOS device has performed well in both bench-top and realistic clinical applications on patients in vivo . hDOS device provides a unique combination of parameters, available for the first time in a fully automated, self-contained platform.
